Selsym Biotech

Founded with a mission to address critical unmet needs in bleeding management, Selsym Biotech is a preclinical stage biotechnology startup focused on developing innovative platelet-mimetic therapies. Their core vision is to enhance patient survival and recovery by providing advanced solutions for uncontrolled bleeding. Selsym Biotech's primary product, SymClot, aims to offer trauma stabilization, cost-effective surgical bleeding treatment, and improved wound healing outcomes through a unique mechanism of action that minimizes immune risks.

Selsym Biotech has garnered attention from notable investors and industry experts due to its groundbreaking approach in the biotech field. The company has achieved significant milestones in preclinical trials, demonstrating the efficacy and safety of its platelet-mimetic technology. By addressing a critical gap in bleeding management, Selsym Biotech is poised to make a substantial impact on both emergency trauma care and surgical procedures, potentially saving countless lives and reducing healthcare costs.